Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Int. J. Mol. Sci. 2008, 9(4), 668-678; doi:10.3390/ijms9040668
Review

CELL-SELEX: Novel Perspectives of Aptamer-Based Therapeutics

, ,  and *
Received: 18 December 2007; in revised form: 3 April 2008 / Accepted: 24 April 2008 / Published: 24 April 2008
(This article belongs to the Special Issue Nucleic Acid Derivatives in Emerging Technologies)
View Full-Text   |   Download PDF [256 KB, uploaded 19 June 2014]
Abstract: Aptamers, single stranded DNA or RNA molecules, generated by a method called SELEX (systematic evolution of ligands by exponential enrichment) have been widely used in various biomedical applications. The newly developed Cell-SELEX (cell based-SELEX) targeting whole living cells has raised great expectations for cancer biology, -therapy and regenerative medicine. Combining nanobiotechnology with aptamers, this technology opens the way to more sophisticated applications in molecular diagnosis. This paper gives a review of recent developments in SELEX technologies and new applications of aptamers.
Keywords: cell-SELEX; aptamer; nanotechnology cell-SELEX; aptamer; nanotechnology
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Guo, K.-T.; Ziemer, G.; Paul, A.; Wendel, H.P. CELL-SELEX: Novel Perspectives of Aptamer-Based Therapeutics. Int. J. Mol. Sci. 2008, 9, 668-678.

AMA Style

Guo K-T, Ziemer G, Paul A, Wendel HP. CELL-SELEX: Novel Perspectives of Aptamer-Based Therapeutics. International Journal of Molecular Sciences. 2008; 9(4):668-678.

Chicago/Turabian Style

Guo, Ke-Tai; Ziemer, Gerhard; Paul, Angela; Wendel, Hans P. 2008. "CELL-SELEX: Novel Perspectives of Aptamer-Based Therapeutics." Int. J. Mol. Sci. 9, no. 4: 668-678.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert